Skp2 and p27kip1 expression in melanocytic nevi and melanoma: An inverse relationship

Journal of Cutaneous Pathology

Volumn 31, Issue 10, 2004, Pages 633-642

  Li, Qing ^a   Murphy, Michael ^b   Ross, Jeffrey ^a   Sheehan, Christine ^a   Carlson, J Andrew ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

CANCER GROWTH; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ADULT; AGED; ARTICLE; CELL NUCLEUS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PIGMENTED NEVUS; PRECANCER; SKIN TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PRECANCEROUS CONDITIONS; PROGNOSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 7444234290     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.00243.x     Document Type: Conference Paper

References (72)

1. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27 (Kip1) and its alterations in tumor cells: a review. J Cell Physiol 2000; 183: 18.
2. Philipp-Staheli J, Kim KH, Liggitt D, Gurley KE, Longton G, Kemp CJ. Distinct roles for p53, p27 (Kip1), and p21 (Cip1) during tumor development. Oncogene 2003; 90: 5.
3. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10.
4. Moreira G Jr, Colleoni GW, Cangi MG, et al. Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol 2003; 12: 128.
5. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998; 153: 681.
6. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259.
7. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231.
8. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159: 941.
9. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730.
10. Kim DH, Lee HI, Nam ES, et al. Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2000; 36: 245.
11. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381.
12. Catzavelos C, Tsao MS, DeBoer G, et al. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999; 59: 684.
13. Fiorentino M, Altimari A, D'Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000; 6: 3966.
14. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998; 153: 305.
15. Bales ES, Dietrich C, Bandyopadhyay D, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113: 1039.
16. Morgan MB, Cowper SE. Expression of p-27 (kip1) in nevi and melanomas. Am J Dermatopathol 1999; 21: 121.
17. Murphy M, Carlson JA. Can we reliably use markers of cell cycle regulation (e.g. Ki-67, p21, p27, p53) to differentiate between benign and malignant skin tumors? J Cutan Pathol 2001; 28: 219.
18. Murphy M, Carlson J, Claffey K, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin dependent kinase inhibitor p27kip1. J Cutan Pathol 2004; 31: 477.
19. Demetrick DJ, Zhang H, Beach DH. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 1996; 73: 104.
20. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193.
21. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207.
22. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27 (Kip1) ubiquitination and degradation is regulated by the SCF (Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661.
23. Bilodeau M, Talarmin H, Ilyin G, et al. Skp2 induction and phosphorylation is associated with the late G1 phase of proliferating rat hepatocytes. FEBS Lett 1999; 452: 247.
24. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27 (Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069.
25. Yeh KH, Kondo T, Zheng J, Tsvetkov LM, Blair J, Zhang H. The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. Biochem Biophys Res Commun 2001; 281: 884.
26. Nakayama KI, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001; 282: 853.
27. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995; 82: 915.
28. Carrano AC, Pagano M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol 2001; 153: 1381.
29. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999; 1: 14.
30. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001; 98: 2515.
31. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27 (Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27 (Kip1) and proliferation index. Blood 2002; 100: 2950.
32. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98: 5043.
33. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61: 7044.
34. Drobnjak M, Melamed J, Taneja S, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003; 9: 2613.
35. Ben-Izhak O, Lahav-Baratz S, Meretyk S, et al. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol 2003; 170: 241.
36. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003; 9: 1756.
37. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003; 21: 722.
38. Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819.
39. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110: 633.
40. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-Expression of p45 (SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27 (KIP1) down-regulation. Mod Pathol 2002; 15: 1227.
41. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161: 207.
42. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002; 160: 1457.
43. Dowen SE, Scott A, Mukherjee G, Stanley MA. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 2003; 105: 326.
44. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003; 278: 41355.
45. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975-2000. In: Bethesda, MD: National Cancer Institute, 2003.
46. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1.
47. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the world-wide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18.
48. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000; 42: 480.
49. Meyers M, Balch CM. Diagnosis and treatment of metastatic melanoma. In: Balch CM, Houghton A, Sober A, Soong S, eds. Cutaneous Melanoma, 3rd edn. St. Louis, MO: Quality Medical Publishing, Inc., 1998: 325.
50. Balch CM, Buzaid AC, Soong SJ, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21: 43.
51. Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS. Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev Mol Diagn 2003; 3: 303.
52. Mu XC, Tran TA, Ross JS, Carlson JA. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol 2000; 27: 242.
53. Murphy M, Signoretti S, Carlson JA, Loda M. P27 protein expression in malignant melanoma: inverse correlation with depth of invasion. J Cutan Pathol 1999; 27: 324 [abstract].
54. Clemente C, Cochran AJ, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization melanoma programme. Hum Pathol 1991; 22: 313.
55. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635.
56. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003; 22: 3087.
57. Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev Mol Diagn 2003; 3: 163.
58. Sauroja I, Smeds J, Vlaykova T, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000; 28: 404.
59. Zhang H, Schneider J, Rosdahl I. Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. Int J Oncol 2002; 21: 43.
60. Zhang H, Rosdahl I. Expression of oncogenes, tumour suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells. Int J Oncol 2001; 19: 1149.
61. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002; 161: 229.
62. Worm J, Bartkova J, Kirkin AF, et al. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000; 19: 5111.
63. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164: 193.
64. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 2000; 97: 10026.
65. St Croix B, Sheehan C, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 (KIP1). J Cell Biol 1998; 142: 557.
66. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27Kip1 safe-guards against inflammatory injury. Nat Med 1998; 4: 575.
67. Ponce-Castaneda MV, Lee MH, Latres E, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55: 1211.
68. Pietenpol JA, Bohlander SK, Sato Y, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995; 55: 1206.
69. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682.
70. Shim EH, Johnson L, Noh HL, et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003; 63: 1583.
71. Ganiatsas S, Dow R, Thompson A, Schulman B, Germain D. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene 2001; 20: 3641.
72. Katner AL, Hoang QB, Gootam P, et al. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27 (Kip1). Prostate 2002; 53: 77.